These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 10534163)

  • 1. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility.
    Baloch ZW; Abraham S; Roberts S; LiVolsi VA
    Hum Pathol; 1999 Oct; 30(10):1166-71. PubMed ID: 10534163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
    Abouhashem NS; Talaat SM
    Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts.
    Wallander M; Layfield LJ; Jarboe E; Emerson L; Liu T; Thaker H; Holden J; Tripp S
    Appl Immunohistochem Mol Morphol; 2010 May; 18(3):231-5. PubMed ID: 20042852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
    Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
    Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical diagnosis of papillary thyroid carcinoma.
    Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
    Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions.
    Palo S; Biligi DS
    Malays J Pathol; 2017 Apr; 39(1):55-67. PubMed ID: 28413206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.
    Lamba Saini M; Weynand B; Rahier J; Mourad M; Hamoir M; Marbaix E
    Diagn Pathol; 2015 Apr; 10():32. PubMed ID: 25907675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma.
    Mai KT; Landry DC; Thomas J; Burns BF; Commons AS; Yazdi HM; Odell PF
    Histopathology; 2001 Jul; 39(1):25-32. PubMed ID: 11454041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications.
    Miettinen M; Kovatich AJ; Kärkkäinen P
    Virchows Arch; 1997 Dec; 431(6):407-13. PubMed ID: 9428928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of HBME-1 and CD56 in follicular variant of papillary carcinoma in children: An immunohistochemical study and their diagnostic utility.
    Skaria PE; Ahmed AA; Yin H; Nicol K; Reid KJ; Singh V
    Pathol Res Pract; 2019 May; 215(5):880-884. PubMed ID: 30711197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma.
    Cameron BR; Berean KW
    J Otolaryngol; 2003 Oct; 32(5):319-22. PubMed ID: 14974863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Papillary and follicular neoplasms of the thyroid gland. Differential immunohistochemical staining with high-molecular-weight keratin and involucrin.
    Liberman E; Weidner N
    Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):42-8. PubMed ID: 10937048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokeratin expression profiles in thyroid carcinomas.
    Lam KY; Lui MC; Lo CY
    Eur J Surg Oncol; 2001 Nov; 27(7):631-5. PubMed ID: 11669590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of cytokeratins and ret in thyroid papillary carcinoma].
    Zhou WX; Xiao Y; Liu TH; Luo YF; Cao JL
    Zhonghua Bing Li Xue Za Zhi; 2003 Dec; 32(6):530-3. PubMed ID: 14761598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.
    Sadiq Q; Sekhri R; Dibaba DT; Zhao Q; Agarwal S
    World J Surg Oncol; 2021 May; 19(1):143. PubMed ID: 33964951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.
    Casey MB; Lohse CM; Lloyd RV
    Endocr Pathol; 2003; 14(1):55-60. PubMed ID: 12746563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
    He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
    Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
    Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
    Pyo JS; Kim DH; Yang J
    Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic utility of CK19 and galectin-3 in differentiating papillary thyroid carcinoma from nonneoplastic lesions of thyroid.
    Prasad PA; Raju K
    J Cancer Res Ther; 2022; 18(3):644-649. PubMed ID: 35900535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.